Scholarlink

<p>Drug-resistant epilepsy (DRE) is a common and debilitating disease, affecting one third of the approximately 70 million people living with epilepsy worldwide. It is defined by the persistence of seizures despite treatment with at least two appropriately chosen antiseizure medication regimens and is associated with lower quality of life and increased risks of mortality, comorbidities and psychosocial dysfunction. In the USA and EU, cenobamate is approved for the treatment of drug-resistant focal seizures and fenfluramine is approved for the treatment of seizures associated with Dravet syndrome, after they significantly reduced seizure frequency during clinical trials. With a promising pipeline of novel pharmacotherapies, there may be a shift emerging in the understanding and treatment of DRE.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider cenobamate and fenfluramine for drug-resistant epilepsy, with development of promising new pharmacotherapies in the pipeline

  • 期刊论文

  • 发表日期：

    2025年8月11日

查看全文
  • Aisling McGuigan

摘要

Drug-resistant epilepsy (DRE) is a common and debilitating disease, affecting one third of the approximately 70 million people living with epilepsy worldwide. It is defined by the persistence of seizures despite treatment with at least two appropriately chosen antiseizure medication regimens and is associated with lower quality of life and increased risks of mortality, comorbidities and psychosocial dysfunction. In the USA and EU, cenobamate is approved for the treatment of drug-resistant focal seizures and fenfluramine is approved for the treatment of seizures associated with Dravet syndrome, after they significantly reduced seizure frequency during clinical trials. With a promising pipeline of novel pharmacotherapies, there may be a shift emerging in the understanding and treatment of DRE.